文献速递淋巴瘤造血干细胞移植与细胞治疗

大剂量90Y-替伊莫单抗联合异基因移植治疗侵袭性大B细胞淋巴瘤有效

Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

这项2期研究评估大剂量90Y-替伊莫单抗联合氟达拉滨和2 Gy全身照射后行HLA相合异基因造血干细胞移植,治疗20例CD20+ B细胞淋巴瘤患者(中位既往4.5线治疗)。中位无进展生存期1.57年,5年总生存率63%,1年非复发死亡率10%,未发生继发性急性髓系白血病/骨髓增生异常综合征。方案可行、安全且有效,超过了预设终点。

要点

  • 大剂量90Y-替伊莫单抗联合减低强度预处理后异基因移植可行且安全。
  • 5年无进展生存率50%,5年总生存率63%,中位总生存期6.45年。
  • 1年非复发死亡率10%,未观察到继发性急性髓系白血病/骨髓增生异常综合征。

核心结论

  • 大剂量90Y-替伊莫单抗联合氟达拉滨和低剂量全身照射后行HLA相合异基因移植,对侵袭性B细胞淋巴瘤可行、安全且有效,超过了预设终点。

研究设计与样本

  • 2期研究,纳入20例CD20+ B细胞淋巴瘤患者,中位既往治疗线数为4.5线,其中14例曾接受自体移植、4例曾接受抗CD19 CAR-T细胞治疗。
  • 患者接受门诊90Y-替伊莫单抗(1.5 mCi/kg,最大120 mCi)、氟达拉滨和2 Gy全身照射后行HLA相合异基因造血干细胞移植。

主要发现

  • 中位90Y-替伊莫单抗活度为113.6 mCi(范围71.2-129.2 mCi),肝脏中位吸收剂量552 cGy(范围499-2411 cGy)。
  • 估计1年和5年无进展生存率分别为55%(95%CI 31-73)和50%(95%CI 27-69),中位无进展生存期1.57年。
  • 估计1年和5年总生存率分别为80%(95%CI 54-92)和63%(95%CI 38-81),中位总生存期6.45年。

临床怎么用

  • 对于侵袭性B细胞淋巴瘤,尤其是多线治疗后复发难治患者,可考虑大剂量90Y-替伊莫单抗联合减低强度预处理后异基因移植。

局限性

  • 研究为单臂2期设计,样本量仅20例,缺乏对照组。
  • 中位随访时间未报告,长期疗效和毒性需进一步随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative for relapsed or refractory B-cell lymphomas (BCLs), although outcomes are worse in aggressive disease, and most patients will still experience relapse. Radioimmunotherapy using 90Y-ibritumomab tiuxetan can induce disease control across lymphoma subtypes in a dose-dependent fashion. We hypothesized that megadoses of 90Y-ibritumomab tiuxetan with reduced-intensity conditioning could safely produce deeper remissions in aggressive BCL further maintained with the immunologic effect of allo-HCT. In this phase 2 study, CD20+ BCL patients received outpatient 90Y-ibritumomab tiuxetan (1.5 mCi/kg; maximum, 120 mCi), fludarabine, and then 2 Gy total body irradiation before HLA-matched allo-HCT. Twenty patients were enrolled after a median of 4.5 prior lines of therapy, including 14 with prior autologous transplant and 4 with prior anti-CD19 chimeric T-cellular therapy. A median 90Y-ibritumomab tiuxetan activity of 113.6 mCi (range, 71.2-129.2 mCi) was administered, delivering a median of 552 cGy to the liver (range, 499-2411 cGy). The estimated 1- and 5-year progression-free survival was 55% (95% confidence interval [CI], 31-73) and 50% (95% CI, 27-69) with a median progression-free survival of 1.57 years. The estimated 1- and 5-year overall survival was 80% (95% CI, 54-92) and 63% (95% CI, 38-81) with a median overall survival of 6.45 years. Sixteen patients (80%) experienced grade 3 or higher toxicities, although nonrelapse mortality was 10% at 1 year. No patients developed secondary acute myeloid leukemia/myelodysplastic syndrome. Megadose 90Y-ibritumomab tiuxetan, fludarabine, and low-dose total body irradiation followed by an HLA-matched allo-HCT was feasible, safe, and effective in treating aggressive BCL, exceeding the prespecified end point while producing nonhematologic toxicities comparable to those of standard reduced-intensity conditioning regimens.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chow VA, Cassaday RD, Gooley TA, et al. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. Blood Adv. 2022. PMID: 34649272. doi:10.1182/bloodadvances.2021005056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。